Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer

General Inclusion Criteria: * Patients with a pathologically confirmed diagnosis of advanced solid tumors or lymphoma. * Tumor progression after receiving standard/approved therapies which may include chemotherapy, targeted agents, radio-immuno conjugates, check point inhibitors, where there is no approved therapy; or the patient is intolerant of standard of care or the patient declines standard of care treatment * One or more metastatic tumors measurable, or evaluable, per RECIST v1.1 Criteria for solid tumors and Lugano Criteria for lymphoma * Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 * Life expectancy of at least 3 months * Age 18 years * Signed, written IRB-approved informed consent * A negative pregnancy test (if female) * Acceptable liver function: * Bilirubin ≤ 1.5 times upper limit of normal * AST (SGOT), ALT (SGPT) and Alkaline phosphatase ≤ 2.5 times upper limit of normal (if liver metastases are present, then ≤ 5 x ULN is allowed) * Acceptable renal function: o Serum creatinine ≤ 1.5 times institutional ULN, OR calculated creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal. * Acceptable hematologic status: * Granulocyte ≥ 1500 cells/mm3 * Platelet count ≥ 100,000 (plt/mm3) * Hemoglobin ≥ 9 g/dL * Urinalysis: o No clinically significant abnormalities * Acceptable coagulation status (for patients on warfarin or other anti-coagulants, a PT/PTT considered by the PI …